Education
About Us
Working with TipRanks
Follow Us
Curis Inc. (CRIS)
:CRIS
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-1.36Last Year’s EPS
-2.03Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: 0.00%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, especially with emavusertib in PCNSL and AML, showing strong potential for future growth. Financial performance improved, though there is a concern about the limited cash runway. Overall, the positive developments in clinical trials outweigh the financial concerns.Company Guidance
During Curis' first quarter 2025 business update call, the company provided several key metrics and updates on their ongoing efforts. In their TakeAim lymphoma study, which evaluates emavusertib in combination with ibrutinib for primary CNS lymphoma (PCNSL), 27 patients with relapsed/refractory PCNSL have been treated, including 7 BTKI-naive patients and 20 BTKI-experienced patients. Among the BTKI-experienced group, 6 out of 13 response-evaluable patients demonstrated a reduction in tumor burden, with 4 achieving complete responses, 3 of which lasted over 6 months. In the BTKI-naive group, all 5 evaluable patients showed objective responses. Additionally, Curis reported a net loss of $10.6 million for the first quarter, with cash and cash equivalents totaling $20.3 million as of March 31, 2025, expected to fund operations into the fourth quarter of 2025. The company continues to focus on enrolling 30 to 40 additional patients for their NDA submission and is planning further data releases at the upcoming ASH conference.Strong Progress in PCNSL Study
The TakeAim lymphoma study evaluating emavusertib in combination with ibrutinib showed promising results with 9 out of 13 BTKI-experienced patients showing tumor reduction. The study is on track to support accelerated submissions in both the U.S. and Europe.
Significant Improvement Over Existing Treatments in AML
Emavusertib showed a 38% composite CR rate in a study with relapsed/refractory AML patients, which is a significant improvement over gilteritinib's 21% CR rate, highlighting emavusertib's novel mechanism of action.
Successful Financial Management
Curis reported a decreased net loss of $10.6 million compared to $11.9 million last year and completed a registered direct financing with net proceeds of $8.8 million.
CRIS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CRIS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $2.45 | $2.19 | -10.61% |
Mar 31, 2025 | $2.32 | $2.10 | -9.48% |
Nov 14, 2024 | $3.93 | $3.98 | +1.27% |
Aug 01, 2024 | $5.48 | $4.94 | -9.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Curis Inc. (CRIS) report earnings?
Curis Inc. (CRIS) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Curis Inc. (CRIS) earnings time?
Curis Inc. (CRIS) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRIS EPS forecast?
CRIS EPS forecast for the fiscal quarter 2025 (Q2) is -1.36.